Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Cadonilimab combined with chemotherapy achieved an 81.4% objective response rate and 97.7% disease control rate in advanced ESCC patients. The treatment demonstrated efficacy across all patient ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

"Achieving breakthrough results in production at high volume is a significant milestone for Silicon Box, as well as for transitioning the industry towards more scalable and low-cost design and ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

A new drug combo is more effective in treating advanced prostate cancer The targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progression Signs show the combo might ...

Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, according to findings published Oct. 7 in the journal Nature Medicine ...

Learn how to build a LEGO puzzle box using standard bricks. This tutorial explains each step of the building process including hidden mechanisms and lock designs made only from LEGO parts. Ideal for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus ...